Elekta Strengthens Cancer Treatment in Croatia with Strategic Acquisition

The latest announcement is out from Elekta AB ( ($SE:EKTA.B) ).

Elekta has acquired assets from its distributor in Croatia, a strategic move to enhance its market position and improve cancer treatment capabilities in the region. This acquisition will allow Elekta to establish a direct presence in Croatia, including an office in Zagreb and the hiring of additional staff, which is expected to positively impact patient care by providing access to advanced cancer treatment technologies. The Croatian Ministry of Health’s order for Elekta’s equipment will address the country’s shortage of radiotherapy units, aligning with Croatia’s National Cancer Plan.

The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK63.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.

More about Elekta AB

Elekta is a leader in precision radiation therapy, dedicated to ensuring access to top-tier cancer care. The company collaborates with customers to create sustainable, outcome-driven, and cost-efficient solutions, aiming to improve patient lives and instill hope. Headquartered in Stockholm, Sweden, Elekta operates in over 40 countries and is listed on Nasdaq Stockholm.

Average Trading Volume: 1,331,597

Current Market Cap: SEK18.87B

See more insights into EKTA.B stock on TipRanks’ Stock Analysis page.